Compare SNTI & SNAL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SNTI | SNAL |
|---|---|---|
| Founded | 2016 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 31.5M | 26.6M |
| IPO Year | 2021 | 2022 |
| Metric | SNTI | SNAL |
|---|---|---|
| Price | $0.42 | $4.98 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $8.50 | N/A |
| AVG Volume (30 Days) | 292.5K | ★ 530.7K |
| Earning Date | 05-06-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 77.31 | ★ 120.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $81,225,622.00 |
| Revenue This Year | N/A | $15.53 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.42 | $0.34 |
| 52 Week High | $2.88 | $5.92 |
| Indicator | SNTI | SNAL |
|---|---|---|
| Relative Strength Index (RSI) | 24.51 | 71.53 |
| Support Level | N/A | $0.65 |
| Resistance Level | $1.02 | $5.92 |
| Average True Range (ATR) | 0.08 | 0.62 |
| MACD | -0.05 | 0.03 |
| Stochastic Oscillator | 4.14 | 61.71 |
Senti Biosciences Holdings Inc, formerly known as Senti Biosciences Inc, is a clinical-stage biotechnology company developing cell and gene therapies using its gene circuit platform for patients with incurable diseases. Its gene circuits, created from proprietary DNA sequences, are designed to reprogram cells to sense, compute, and respond to cellular environments. Its product candidates are to kill cancer cells, spare healthy cells, increase specificity, and control drug expression. Its candidate, SENTI-202, is a logic-gated off-the-shelf CAR-NK cell therapy for blood cancers, currently in a Phase 1 clinical trial in the United States and Australia for relapsed or refractory hematological malignancies, including Acute Myeloid Leukemia (AML).
Snail Inc is an independent developer and publisher of interactive digital entertainment for consumers around the world, with a portfolio of premium games designed for use on a variety of platforms, including consoles, PC's, and mobile devices. The geographic presence of the company is in the United States and the International market, where the majority of its revenue comes from the United States. The Company has one operating and reportable segment. The company operates in the USA, the UK and Other Countries.